BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 29, 2003
View Archived Issues
Novogen Cancer Subsidiary Files IPO, Seeks Up To $13M
Read More
Chromosome 15's 4 Mutant Genes Focus Hotspots For Derangements In Michigan, Penn Research Centers
Read More
Hollis-Eden Raises $62.5M; This Time In Public Offering
Read More
Angiotech Garners $218.8M With Follow-On Public Stock Offering
Read More
Appointments And Advancements
Read More
Other News To Note
Read More
After Phase II Miss, HGS Stops Repifermin Venous Ulcers Work
Human Genome Sciences Inc. said it would terminate development of repifermin in chronic venous ulcers following a disappointing Phase II trial. (BioWorld Today)
Read More